Date: 23rd October 2026

To,

National Stock Exchange of India Limited Exchange Plaza, Block G, C/1, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Symbol: SAPPHIRE	**BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 543397

Dear Sir/Madam,

Subject: Newspaper Advertisement pertaining to Financial Results for the quarter and half year ended 30th September 2026

Pursuant to Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we enclose herewith the copy of newspaper advertisement published in Business Standard (English - All Editions & Hindi-Delhi Edition) pertaining to financial results of the Company for the quarter and half year ended 30th September 2026.

You are requested to kindly take the same on record.

Thanking you,

For Sapphire Foods India Limited

SACHIN TUKARAM DUDAM
Digitally signed by SACHIN TUKARAM DUDAM
Date: 2026.10.23 14:32:39 +05'30'

SAPPHIRE FOODS INDIA LIMITED MUMBAI

Sachin Dudam
Company Secretary and Compliance Officer

Encl.: As above

J. RESTATED AUDITED FINANCIALS FOR THE PREVIOUS THREE FINANCIAL YEARS PRIOR TO THE DATE OF LISTING

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
I. Assets				
(1) Non-Current Assets	2,77,076.75	-	-	NA
(2) Current Assets:				
(a) Cash and cash equivalents	95.02	0.76	1.00	NA
(b) Bank Balance other than (a) above	479.14	-	-	NA
(c) Other Current Assets	55,552.79	-	-	NA
Total Assets	**3,33,203.70**	**0.76**	**1.00**	**NA**
II. Equity and Liabilities				
Equity				
(a) Equity share capital	3,351.34@	1.00	1.00	NA
(b) Other Equity	1,23,438.28	(0.38)	(0.16)	NA
Total Equity	**1,26,789.62**	**0.62**	**0.84**	NA
Liabilities				
(1) Non-current liabilities	92,837.30	-	-	NA
(2) Current Liabilities				
(a) Trade Payable	63,805.78	-	-	NA
(b) Financial Liabilities	45,644.52	0.14	0.16	NA
(c) Other Current Liabilities	4,126.48	-	-	NA
Total Equity and Liabilities	**3,33,203.70**	**0.76**	**1.00**	**NA**

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

@The Equity Shares were allotted by the Company at its Board Meeting held on September 08, 2026. Accordingly, the Share Capital has been presented under the head "Equity Share Suspense Account" pending allotment.

RESTATED STATEMENT OF PROFIT AND LOSS OF THE COMPANY IS AS UNDER:

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
Revenue from operations	2,54,189.00	-	-	NA
Other Income	1.13	-	-	NA
Total Income	**2,54,190.13**	**-**	**-**	NA
Expenses				
Cost of material consumed	37,221.65	**-**	**-**	NA
Excise Duty on Sales	1,85,804.88	**-**	**-**	NA
Purchase of stock-in-trade	2,910.57	**-**	**-**	NA
Change in inventories	1,204.41	**-**	**-**	NA
Employee benefits expense	1,206.56	**-**	**-**	NA
Finance costs	1,350.46	**-**	**-**	NA
Depreciation	2,674.01	**-**	**-**	NA
Other Expenses	13,831.77	0.22	0.16	NA
Total Expenses	**2,46,204.31**	**0.22**	**0.16**	NA
Profit/(Loss) before exceptional items and tax	**7,985.82**	**(0.22)**	**(0.16)**	NA
Exceptional items	-	-	-	NA
Profit/(Loss) before tax	**7,985.82**	**(0.22)**	**(0.16)**	NA
Tax Expense				
(a) Current tax	1,032.39	-	-	NA
(b) Deferred tax expense/ (income)	994.12	-	-	NA
(c) Income Tax Earlier Year	**-**	**-**	**-**	NA
Profit/(Loss) for the period	**5,959.31**	**(0.22)**	**(0.16)**	NA
Other Comprehensive Income	**(5.53)**	**-**	**-**	NA
Total Comprehensive Income for the period	**5,953.78**	**(0.22)**	**(0.16)**	NA
Earnings per equity share				
Basic (Nominal value of INR 5 each)	8.89	(1.10)	(2.30)	NA
Diluted (Nominal value of INR 5 each)	8.89	(1.10)	(2.30)	NA

Note: Pursuant to the applicable accounting standards, the historical share capital and per share information have been adjusted, wherever applicable, to give effect to the split of equity shares from INR 10/- to INR 5/- each and ensure comparability across the periods presented.

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

RESTATED STATEMENT OF CASH FLOW OF THE COMPANY IS AS UNDER:

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
A. **Cash flow from operating activities**				
Net profit/(loss) before tax and extraordinary items	7,985.82	(0.22)	(0.16)	NA
Operating profit/(loss) before working capital changes	12,009.79	(0.22)	(0.16)	NA
Add: Working Capital Changes:	**(6,865.63)**	-	-	NA
Increase/ (decrease) in Trade & Other Receivables	1,539.01	-	-	NA
Increase/ (decrease) in Trade payables & Other Payables	(1,846.93)	(0.02)	0.16	NA
Increase/ (decrease) in inventories	(6,557.71)	-	-	NA
Cash generated from/(used in) operations	**5,144.16**	(0.24)	-	NA
Income Tax Paid	(1,032.39)	-	-	NA
Net cash flow from / (used in) operating activities	**4,111.77**	-	-	NA
B. **Net cash flow from / (used in) investing activities**	**(5,329.50)**	-	-	NA
C. **Net cash flow from / (used in) financing activities**	**864.58**	-	1.00	NA
D. **Exchange difference in translating the financial statements**	-	-	-	NA
Net increase/(decrease) in cash and cash equivalents	(353.15)	(0.24)	1.00	NA
Cash and Cash Equivalents, Beginning of the year	0.76	1.00	-	NA
Transferred pursuant to the scheme	447.41			
Cash and Cash Equivalents, Ending of the year	**95.02**	**0.76**	**1.00**	NA

** The demerger contemplated in the Scheme have been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

K. LATEST RESTATED AUDITED FINANCIAL STATEMENTS ALONG WITH NOTES TO ACCOUNTS

The copy of the Restated Audited Financial Statements, along with the notes to accounts, may be accessed through the following link: https://iglspirits.com/wp-content/uploads/Financial_June2026.pdf

The same is also available at page 82 in the Information memorandum.

L. CHANGE IN ACCOUNTING POLICIES IN THE LAST THREE YEARS AND THEIR EFFECT ON PROFITS AND RESERVES

There is no change in accounting policies of the company in the last three years.

M. SUMMARY TABLE OF CONTINGENT LIABILITIES AS DISCLOSED IN THE RESTATED FINANCIAL STATEMENTS

(in INR, In Lacs)

S. No.	Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
1.	NA	NIL	NIL	NIL	NA
Total		**NIL**	**NIL**	**NIL**	**NA**

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

N. SUMMARY TABLE OF RELATED PARTY TRANSACTIONS IN LAST 3 YEARS AS DISCLOSED IN THE RESTATED FINANCIAL STATEMENTS

(In INR, in Lacs)

Nature of transaction	Related party with whom transaction has taken place	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
Proceeds from issue of share capital	India Glycols Limited	NIL	NIL	1.00	NA

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

O. DETAILS OF ITS OTHER GROUP COMPANIES INCLUDING THEIR CAPITAL STRUCTURE AND FINANCIAL STATEMENTS

Set out below are the Group Companies of our Company as per the SEBI ICDR Regulations and the Materiality Policy for Determination of Group Companies adopted by the Company:

(i.) India Glycols Limited

India Glycols Limited is a public listed company incorporated under the provisions of the Companies Act, 1956 under the corporate identity number L24111UR1983PLC009097. Post the Demerger envisaged in the Scheme of Arrangement, IGL continues to remain engaged in the business of manufacturing and marketing of Bio-based Specialities & Performance Chemicals.

Website: www.indiaglycols.com

Capital Structure

Share Capital of the Company	
Particulars	**Aggregate Value at Face Value (In ₹)**
Authorized Share Capital	
9,00,00,000 Equity Shares of INR 5/- each	45,00,00,000
Total	**45,00,00,000**
Issued, Subscribed and Paid Up Share Capital	
6,70,26,765 Equity Shares of INR 5/- each	33,51,33,825
Total	**33,51,33,825**

Financial Information

The following information has been derived from the consolidated audited financial statements of IGL for the last three financial years:

(in INR, in Lacs)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24
Equity Capital	3,351.34	3,096.15	3,096.15
Other equity	2,89,926.51	2,22,491.51	2,02,005.52
Total Income	9,83,156.16	9,05,350.43	7,94,727.00
Profit/(loss) for the year	29,276.18	23,092.45	17,299.31
EPS (Basic)	45.95	37.29	27.94
EPS (Diluted)	45.95	37.29	27.94
Net Asset Value	2,93,277.85	2,25,587.66	2,05,101.67

Note: Pursuant to the applicable accounting standards, the historical share capital and per share information have been adjusted, wherever applicable, to give effect to the split of equity shares from INR 10/- to INR 5/- each and ensure comparability across the periods presented.

The copy of the Audited Financial Statements (Consolidated and Standalone) of the abovementioned Group Company is available at the website of the Company at https://www.indiaglycols.com/.

P. Internal Risk Factors

1. ***Dependence on Availability of Raw Materials***

Our operations depend upon the continuous availability of agricultural products, grains, molasses and other raw materials required for the manufacture of spirits and related products. The timely procurement of such raw materials in the required quantities and quality is critical for maintaining uninterrupted production and operational efficiency.

Any disruption in the availability of raw materials due to supply shortages, procurement delays, quality issues, transportation disruptions, seasonal variations or volatility in supply conditions may adversely affect production efficiency, increase operating costs and impact profitability. Any such event may adversely affect our business, financial condition and results of operations.

2. ***Risks Associated with Manufacturing and Distillation Processes***

The manufacture of spirits involves complex fermentation, distillation, blending and other manufacturing processes requiring strict adherence to established process parameters, operational controls and quality standards.

Any breakdown, inefficiency, process deviation, equipment malfunction, utility interruption or inadequacy in manufacturing controls may result in lower production yields, product quality concerns, production losses or increased operating costs. In addition, any failure to consistently maintain required manufacturing standards may adversely affect operational efficiency and profitability. Any such event may adversely affect our business, financial condition and results of operations.

3. ***Regulatory Licensing and Compliance Management Risks***

Our business is subject to various licences, permits, registrations, approvals and regulatory requirements issued by governmental and regulatory authorities. Such approvals are subject to periodic renewal, review and ongoing compliance obligations.

Any failure on our part to obtain, renew, maintain or comply with the conditions attached to such licences, permits or approvals, whether due to internal procedural lapses, non-compliance, inadequate documentation or failure to implement corrective actions in a timely manner, may result in suspension, cancellation or delay in obtaining such approvals. Any such occurrence may reduce manufacturing efficiency, impact product quality and adversely affect the profitability of our operations.

4. ***Quality Control and Product Consistency Risks***

Maintaining consistent product quality and adherence to prescribed specifications is critical for regulatory compliance, customer acceptance and the continued success of our products in the market. Our operations require effective quality control systems and continuous monitoring throughout the manufacturing process.

Any deficiencies in our quality control procedures, testing practices, production controls or quality management systems may result in product quality concerns, rejection of products, product recalls, regulatory penalties or loss of customer confidence. Such events may adversely affect our reputation, business prospects, financial condition and results of operations.

5. ***Storage, Handling and Inventory Management Risks***

Spirits and certain raw materials used in our operations require specialised storage conditions, controlled handling procedures and continuous monitoring due to their flammable nature. Effective inventory management is essential to preserve product quality, minimise losses and ensure compliance with applicable safety and regulatory requirements.

Any leakage, pilferage, evaporation loss, deterioration, contamination, improper storage, mishandling during transportation or deficiencies in inventory control systems may result in financial losses, inventory shortages, operational disruptions or regulatory action. Such incidents may result in inventory losses, increased compliance costs and operational disruptions.

6. ***Dependence on Policy Framework and Blending Mandates***

Our spirits and bio-fuel operations are influenced by prevailing government policies, regulatory frameworks and blending mandates applicable to the industry. The effective implementation of such policies and our ability to align operational planning and supply schedules with applicable requirements are important for sustaining revenues and business growth.

Any inability on our part to effectively align operations, production planning or supply schedules with such policy frameworks, mandates or regulatory requirements may adversely affect revenues, operational efficiency and profitability. Any such event may adversely affect our business, financial condition and results of operations.

7. ***Health, Safety and Environmental Management Risks***

Our manufacturing activities involve the handling, storage and processing of flammable and hazardous materials. Accordingly, we are required to maintain appropriate health, safety and environmental management systems and comply with applicable environmental and industrial safety regulations.

Any failure in our internal safety practices, environmental controls, operational procedures, employee training programmes or monitoring mechanisms may result in accidents, fires, environmental incidents, operational disruptions or liabilities. Such incidents may expose us to penalties, legal liabilities, remediation costs and reputational damage, which could adversely affect our business, financial condition and results of operations.

8. ***Risks Relating to Capacity Utilisation and Expansion***

Our financial performance is dependent upon the efficient utilisation of our manufacturing capacities and the effective execution of capacity expansion initiatives. The profitability of our operations is influenced by our ability to optimise production levels, maintain operational efficiency and effectively manage capital investments.

Any under-utilisation of existing capacities, delay in expansion projects, cost overruns, implementation challenges or operational inefficiencies may adversely affect production levels, operating margins and returns on investment. Any such circumstances may reduce operational efficiency, affect expected returns on capital investments and limit future growth opportunities.

Q. OUTSTANDING LITIGATIONS AND DEFAULTS OF THE TRANSFEREE ENTITY, PROMOTERS, DIRECTORS OR ANY OF THE GROUP COMPANIES

A summary of pending criminal proceedings, taxation proceedings, actions taken by statutory or regulatory authorities and other material litigation proceedings involving us, our Directors, our Promoters and our Group Companies is set out below:

S. No.	Name of the entity	Criminal Proceedings	Tax Proceedings	Statutory/Regulatory Proceedings	Material civil litigation
A.	**Litigations involving our Company**				
	Against our Company	NIL	NIL	NIL	NIL
	By our Company	20	3	NIL	7
B.	**Directors**				
	Against our Directors	4	NIL	NIL	4
	By our Directors	1	NIL	NIL	NIL
C.	**Promoters**				
	Against our Promoters	NIL	NIL	NIL	NIL
	By our Promoters	NIL	NIL	NIL	1
D.	**Subsidiary**				
	Against our Subsidiary	NA	NA	NA	NA
	By our Subsidiary	NA	NA	NA	NA
E.	**Litigation involving Group Company having material impact on our Company**				
	Against our Group Companies	NIL	6	NIL	5
	By our Group Companies	5	NIL	NIL	6

Kindly refer to the Information Memorandum available on the Company's website for complete details.

R. REGULATORY ACTION, IF ANY - DISCIPLINARY ACTION TAKEN BY SEBI OR STOCK EXCHANGES AGAINST THE PROMOTERS IN LAST 5 FINANCIAL YEARS:

NIL

S. BRIEF DETAILS OF OUTSTANDING CRIMINAL PROCEEDINGS AGAINST THE PROMOTERS:

NIL

T. PARTICULARS OF HIGH, LOW AND AVERAGE PRICES OF THE SHARES OF THE LISTED TRANSFEROR ENTITY DURING THE PRECEDING THREE YEARS:

BSE:

Fiscal Year	High Price	Date of High Price	Volume on date of High Price (No. of Equity Shares)	Low Price	Date of Low Price	Volume on date of Low Price (No. of Equity Shares)	Average Market Price of the Equity Shares for the year
25-26	2,139.30	30.06.2025	7,574	793.95	27.01.2026	11,792	1229.50
24-25	1,545	14.10.2024	13,769	685	05.06.2024	7,623	1132.62
23-24	978.9	05.02.2024	32,085	514	25.04.2023	15,025	713.82

NSE:

Fiscal Year	High Price	Date of High Price	Volume on date of High Price (No. of Equity Shares	Low Price	Date of Low Price	Volume on date of Low Price (No. of Equity Shares)	Average Market Price of the Equity Shares for the year
25-26	2,138	30.06.2025	2,18,801	792.50	27.01.2026	1,02,961	1229.87
24-25	1,548.95	14.10.2024	3,08,209	678.55	05.06.2024	1,42,062	1,133.20
23-24	976	05.02.2024	6,57,772	512.35	25.04.2023	1,31,980	713.95

U. ANY MATERIAL DEVELOPMENT AFTER THE DATE OF THE BALANCE SHEET:

1. Our Company received In-Principle approval from both BSE and NSE vide letter no. DCS/AMAL/IP/TS/278/2026-27 dated October 14, 2026 and letter no. NSE/LIST/204 dated October 15, 2026 respectively.
2. Further, our Company was also granted an exemption from the application of Rule 19(2) (b) of the Securities Contracts (Regulation) Rules, 1957 by the SEBI vide the letter no. I/23931/2026 dated October 16, 2026.
3. Except as disclosed above and in the Information Memorandum, to the knowledge of the Company, there are no circumstances which have arisen since the last Audited Financial Statements disclosed in the Information Memorandum which may materially or adversely affect or are likely to affect the Company's operations, profitability or value of the assets.

V. SUCH OTHER INFORMATION AS MAY BE SPECIFIED BY THE BOARD FROM TIME TO TIME

The Information Memorandum shall be made available on the Company's website at https://iglspirits.com/.

For and on behalf of Board of
IGL Spirits Limited

Sd/-
Ishan Khanna
Company Secretary and Compliance Officer
Membership No: A53517

Place : Noida, Uttar Pradesh
Date : October 22, 2026

SapphireFoods

Sapphire Foods India Limited

Registered Office: SCO – 328, Sector – 9, Panchkula – 134109, Haryana
Corporate Office: 702, Prism Tower, A Wing, Mindspace, Link Road, Goregaon (West), Mumbai - 400062
Corporate Identification Number (CIN): L55204HR2009PLC145722 **Tel No.:** 022 67522300
Email: investor@sapphirefoods.in **Website:** www.sapphirefoods.in

Statement of Unaudited Financial Results (Standalone and Consolidated) for quarter and half year ended on 30th September 2026

[Regulation 33 read with Regulation 47 of the SEBI (LODR) Regulations, 2015]

The Board of Directors at its meeting held on 22nd October 2026 inter-alia, considered and approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2026. The Financial Results alongwith Limited Review Reports are available on Company website at https://www.sapphirefoods.in/investors-relation/financials and can be accessed by scanning the QR Code.

For & On Behalf of the Board of Directors
Sd/-
Sanjay Purohit
Whole-time Director & Group CEO
DIN: 00117676

Place: Mumbai
Date: 22 nd October 2026

Glenmark
A new way for a new world

GLENMARK PHARMACEUTICALS LIMITED

CIN: L24299MH1977PLC019982

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026.

Tel No.: +91 22 4018 9999 • **Fax No.:** +91 22 4018 9986

PUBLIC NOTICE

Notice is hereby given to all concerned that, pursuant to the notification S.O. 5690 (E), dated 17th October, 2026, issued by National Pharmaceutical Pricing Authority ("NPPA") in relation to Trade Margin Rationalisation (TMR), intended to ensure the availability of non-scheduled anti-cancer drugs at affordable prices, the revised Maximum Retail Price ("MRP"), inclusive of GST, applicable to Glenmark products covered under TMR framework shall take effect from 9th November 2026 and shall be as set forth below:

The revised MRP of the applicable Glenmark products may be accessed by scanning the QR code.

All channel partners of Glenmark, including distributors, stockists, retailers, hospitals, health centers etc. are hereby advised and required to give effect to the revised MRP with effect from 9th November, 2026 to ensure that the entire benefit of the applicable reduction in MRP is duly passed on to all customers.

J. RESTATED AUDITED FINANCIALS FOR THE PREVIOUS THREE FINANCIAL YEARS PRIOR TO THE DATE OF LISTING

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
I. Assets				
(1) Non-Current Assets	2,77,076.75	-	-	NA
(2) Current Assets:				
(a) Cash and cash equivalents	95.02	0.76	1.00	NA
(b) Bank Balance other than (a) above	479.14	-	-	NA
(c) Other Current Assets	55,552.79	-	-	NA
Total Assets	**3,33,203.70**	**0.76**	**1.00**	**NA**
II. Equity and Liabilities				
Equity				
(a) Equity share capital	3,351.34@	1.00	1.00	NA
(b) Other Equity	1,23,438.28	(0.38)	(0.16)	NA
Total Equity	**1,26,789.62**	**0.62**	**0.84**	NA
Liabilities				
(1) Non-current liabilities	92,837.30	-	-	NA
(2) Current Liabilities				
(a) Trade Payable	63,805.78	-	-	NA
(b) Financial Liabilities	45,644.52	0.14	0.16	NA
(c) Other Current Liabilities	4,126.48	-	-	NA
Total Equity and Liabilities	**3,33,203.70**	**0.76**	**1.00**	**NA**

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

@The Equity Shares were allotted by the Company at its Board Meeting held on September 08, 2026. Accordingly, the Share Capital has been presented under the head "Equity Share Suspense Account" pending allotment.

RESTATED STATEMENT OF PROFIT AND LOSS OF THE COMPANY IS AS UNDER:

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
Revenue from operations	2,54,189.00	-	-	NA
Other Income	1.13	-	-	NA
Total Income	**2,54,190.13**	**-**	**-**	NA
Expenses				
Cost of material consumed	37,221.65	-	-	NA
Excise Duty on Sales	1,85,804.88	-	-	NA
Purchase of stock-in-trade	2,910.57	-	-	NA
Change in inventories	1,204.41	-	-	NA
Employee benefits expense	1,206.56	-	-	NA
Finance costs	1,350.46	-	-	NA
Depreciation	2,674.01	-	-	NA
Other Expenses	13,831.77	0.22	0.16	NA
Total Expenses	**2,46,204.31**	**0.22**	**0.16**	NA
Profit/(Loss) before exceptional items and tax	**7,985.82**	**(0.22)**	**(0.16)**	NA
Exceptional items	-	-	-	NA
Profit/(Loss) before tax	**7,985.82**	**(0.22)**	**(0.16)**	NA
Tax Expense				
(a) Current tax	1,032.39	-	-	NA
(b) Deferred tax expense/ (income)	994.12	-	-	NA
(c) Income Tax Earlier Year	-	-	-	NA
Profit/(Loss) for the period	**5,959.31**	**(0.22)**	**(0.16)**	NA
Other Comprehensive Income	**(5.53)**	**-**	**-**	NA
Total Comprehensive Income for the period	**5,953.78**	**(0.22)**	**(0.16)**	NA
Earnings per equity share				
Basic (Nominal value of INR 5 each)	8.89	(1.10)	(2.30)	NA
Diluted (Nominal value of INR 5 each)	8.89	(1.10)	(2.30)	NA

Note: Pursuant to the applicable accounting standards, the historical share capital and per share information have been adjusted, wherever applicable, to give effect to the split of equity shares from INR 10/- to INR 5/- each and ensure comparability across the periods presented.

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

RESTATED STATEMENT OF CASH FLOW OF THE COMPANY IS AS UNDER:

(In INR, in Lacs)

Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
A. **Cash flow from operating activities**				
Net profit/(loss) before tax and extraordinary items	7,985.82	(0.22)	(0.16)	NA
Operating profit/(loss) before working capital changes	12,009.79	(0.22)	(0.16)	NA
Add: Working Capital Changes:	**(6,865.63)**	-	-	NA
Increase/ (decrease) in Trade & Other Receivables	1,539.01	-	-	NA
Increase/ (decrease) in Trade payables & Other Payables	(1,846.93)	(0.02)	0.16	NA
Increase/ (decrease) in inventories	(6,557.71)	-	-	NA
Cash generated from/(used in) operations	**5,144.16**	(0.24)	-	NA
Income Tax Paid	(1,032.39)	-	-	NA
Net cash flow from / (used in) operating activities	**4,111.77**	-	-	NA
B. **Net cash flow from / (used in) investing activities**	**(5,329.50)**	-	-	NA
C. **Net cash flow from / (used in) financing activities**	**864.58**	-	1.00	NA
D. **Exchange difference in translating the financial statements**	-	-	-	NA
Net increase/(decrease) in cash and cash equivalents	(353.15)	(0.24)	1.00	NA
Cash and Cash Equivalents, Beginning of the year	0.76	1.00	-	NA
Transferred pursuant to the scheme	447.41			
Cash and Cash Equivalents, Ending of the year	**95.02**	**0.76**	**1.00**	NA

** The demerger contemplated in the Scheme have been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

K. LATEST RESTATED AUDITED FINANCIAL STATEMENTS ALONG WITH NOTES TO ACCOUNTS

The copy of the Restated Audited Financial Statements, along with the notes to accounts, may be accessed through the following link: https://iglspirits.com/wp-content/uploads/Financial_June2026.pdf

The same is also available at page 82 in the Information memorandum.

L. CHANGE IN ACCOUNTING POLICIES IN THE LAST THREE YEARS AND THEIR EFFECT ON PROFITS AND RESERVES

There is no change in accounting policies of the company in the last three years.

M. SUMMARY TABLE OF CONTINGENT LIABILITIES AS DISCLOSED IN THE RESTATED FINANCIAL STATEMENTS

(in INR, In Lacs)

S. No.	Particulars	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
1.	NA	NIL	NIL	NIL	NA
Total		**NIL**	**NIL**	**NIL**	**NA**

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

N. SUMMARY TABLE OF RELATED PARTY TRANSACTIONS IN LAST 3 YEARS AS DISCLOSED IN THE RESTATED FINANCIAL STATEMENTS

(In INR, in Lacs)

Nature of transaction	Related party with whom transaction has taken place	Stub-Period ended on 30.06.2026*	FY 2025-26	FY 2024-25	FY 2023-24$
Proceeds from issue of share capital	India Glycols Limited	NIL	NIL	1.00	NA

** The demerger contemplated in the Scheme has been given effect from the Appointed Date (i.e. April 1, 2026).*

$As the Company was incorporated during FY 2024–25, financial information for FY 2023–24 is not applicable.

O. DETAILS OF ITS OTHER GROUP COMPANIES INCLUDING THEIR CAPITAL STRUCTURE AND FINANCIAL STATEMENTS

Set out below are the Group Companies of our Company as per the SEBI ICDR Regulations and the Materiality Policy for Determination of Group Companies adopted by the Company:

(i.) India Glycols Limited

India Glycols Limited is a public listed company incorporated under the provisions of the Companies Act, 1956 under the corporate identity number L24111UR1983PLC009097. Post the Demerger envisaged in the Scheme of Arrangement, IGL continues to remain engaged in the business of manufacturing and marketing of Bio-based Specialities & Performance Chemicals.

Website: www.indiaglycols.com

Capital Structure

Share Capital of the Company	
Particulars	**Aggregate Value at Face Value (In ₹)**
Authorized Share Capital	
9,00,00,000 Equity Shares of INR 5/- each	45,00,00,000
Total	**45,00,00,000**
Issued, Subscribed and Paid Up Share Capital	
6,70,26,765 Equity Shares of INR 5/- each	33,51,33,825
Total	**33,51,33,825**

Financial Information

The following information has been derived from the consolidated audited financial statements of IGL for the last three financial years:

(in INR, in Lacs)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24
Equity Capital	3,351.34	3,096.15	3,096.15
Other equity	2,89,926.51	2,22,491.51	2,02,005.52
Total Income	9,83,156.16	9,05,350.43	7,94,727.00
Profit/(loss) for the year	29,276.18	23,092.45	17,299.31
EPS (Basic)	45.95	37.29	27.94
EPS (Diluted)	45.95	37.29	27.94
Net Asset Value	2,93,277.85	2,25,587.66	2,05,101.67

Note: Pursuant to the applicable accounting standards, the historical share capital and per share information have been adjusted, wherever applicable, to give effect to the split of equity shares from INR 10/- to INR 5/- each and ensure comparability across the periods presented.

The copy of the Audited Financial Statements (Consolidated and Standalone) of the abovementioned Group Company is available at the website of the Company at https://www.indiaglycols.com/.

P. Internal Risk Factors

1. ***Dependence on Availability of Raw Materials***

Our operations depend upon the continuous availability of agricultural products, grains, molasses and other raw materials required for the manufacture of spirits and related products. The timely procurement of such raw materials in the required quantities and quality is critical for maintaining uninterrupted production and operational efficiency.

Any disruption in the availability of raw materials due to supply shortages, procurement delays, quality issues, transportation disruptions, seasonal variations or volatility in supply conditions may adversely affect production efficiency, increase operating costs and impact profitability. Any such event may adversely affect our business, financial condition and results of operations.

2. ***Risks Associated with Manufacturing and Distillation Processes***

The manufacture of spirits involves complex fermentation, distillation, blending and other manufacturing processes requiring strict adherence to established process parameters, operational controls and quality standards.

Any breakdown, inefficiency, process deviation, equipment malfunction, utility interruption or inadequacy in manufacturing controls may result in lower production yields, product quality concerns, production losses or increased operating costs. In addition, any failure to consistently maintain required manufacturing standards may adversely affect operational efficiency and profitability. Any such event may adversely affect our business, financial condition and results of operations.

3. ***Regulatory Licensing and Compliance Management Risks***

Our business is subject to various licences, permits, registrations, approvals and regulatory requirements issued by governmental and regulatory authorities. Such approvals are subject to periodic renewal, review and ongoing compliance obligations.

Any failure on our part to obtain, renew, maintain or comply with the conditions attached to such licences, permits or approvals, whether due to internal procedural lapses, non-compliance, inadequate documentation or failure to implement corrective actions in a timely manner, may result in suspension, cancellation or delay in obtaining such approvals. Any such occurrence may reduce manufacturing efficiency, impact product quality and adversely affect the profitability of our operations.

4. ***Quality Control and Product Consistency Risks***

Maintaining consistent product quality and adherence to prescribed specifications is critical for regulatory compliance, customer acceptance and the continued success of our products in the market. Our operations require effective quality control systems and continuous monitoring throughout the manufacturing process.

Any deficiencies in our quality control procedures, testing practices, production controls or quality management systems may result in product quality concerns, rejection of products, product recalls, regulatory penalties or loss of customer confidence. Such events may adversely affect our reputation, business prospects, financial condition and results of operations.

5. ***Storage, Handling and Inventory Management Risks***

Spirits and certain raw materials used in our operations require specialised storage conditions, controlled handling procedures and continuous monitoring due to their flammable nature. Effective inventory management is essential to preserve product quality, minimise losses and ensure compliance with applicable safety and regulatory requirements.

Any leakage, pilferage, evaporation loss, deterioration, contamination, improper storage, mishandling during transportation or deficiencies in inventory control systems may result in financial losses, inventory shortages, operational disruptions or regulatory action. Such incidents may result in inventory losses, increased compliance costs and operational disruptions.

6. ***Dependence on Policy Framework and Blending Mandates***

Our spirits and bio-fuel operations are influenced by prevailing government policies, regulatory frameworks and blending mandates applicable to the industry. The effective implementation of such policies and our ability to align operational planning and supply schedules with applicable requirements are important for sustaining revenues and business growth.

Any inability on our part to effectively align operations, production planning or supply schedules with such policy frameworks, mandates or regulatory requirements may adversely affect revenues, operational efficiency and profitability. Any such event may adversely affect our business, financial condition and results of operations.

7. ***Health, Safety and Environmental Management Risks***

Our manufacturing activities involve the handling, storage and processing of flammable and hazardous materials. Accordingly, we are required to maintain appropriate health, safety and environmental management systems and comply with applicable environmental and industrial safety regulations.

Any failure in our internal safety practices, environmental controls, operational procedures, employee training programmes or monitoring mechanisms may result in accidents, fires, environmental incidents, operational disruptions or liabilities. Such incidents may expose us to penalties, legal liabilities, remediation costs and reputational damage, which could adversely affect our business, financial condition and results of operations.

8. ***Risks Relating to Capacity Utilisation and Expansion***

Our financial performance is dependent upon the efficient utilisation of our manufacturing capacities and the effective execution of capacity expansion initiatives. The profitability of our operations is influenced by our ability to optimise production levels, maintain operational efficiency and effectively manage capital investments.

Any under-utilisation of existing capacities, delay in expansion projects, cost overruns, implementation challenges or operational inefficiencies may adversely affect production levels, operating margins and returns on investment. Any such circumstances may reduce operational efficiency, affect expected returns on capital investments and limit future growth opportunities.

Q. OUTSTANDING LITIGATIONS AND DEFAULTS OF THE TRANSFEREE ENTITY, PROMOTERS, DIRECTORS OR ANY OF THE GROUP COMPANIES

A summary of pending criminal proceedings, taxation proceedings, actions taken by statutory or regulatory authorities and other material litigation proceedings involving us, our Directors, our Promoters and our Group Companies is set out below:

S. No.	Name of the entity	Criminal Proceedings	Tax Proceedings	Statutory/Regulatory Proceedings	Material civil litigation
A.	**Litigations involving our Company**				
	Against our Company	NIL	NIL	NIL	NIL
	By our Company	20	3	NIL	7
B.	**Directors**				
	Against our Directors	4	NIL	NIL	4
	By our Directors	1	NIL	NIL	NIL
C.	**Promoters**				
	Against our Promoters	NIL	NIL	NIL	NIL
	By our Promoters	NIL	NIL	NIL	1
D.	**Subsidiary**				
	Against our Subsidiary	NA	NA	NA	NA
	By our Subsidiary	NA	NA	NA	NA
E.	**Litigation involving Group Company having material impact on our Company**				
	Against our Group Companies	NIL	6	NIL	5
	By our Group Companies	5	NIL	NIL	6

Kindly refer to the Information Memorandum available on the Company's website for complete details.

R. REGULATORY ACTION, IF ANY - DISCIPLINARY ACTION TAKEN BY SEBI OR STOCK EXCHANGES AGAINST THE PROMOTERS IN LAST 5 FINANCIAL YEARS:

NIL

S. BRIEF DETAILS OF OUTSTANDING CRIMINAL PROCEEDINGS AGAINST THE PROMOTERS:

NIL

T. PARTICULARS OF HIGH, LOW AND AVERAGE PRICES OF THE SHARES OF THE LISTED TRANSFEROR ENTITY DURING THE PRECEDING THREE YEARS:

BSE:

Fiscal Year	High Price	Date of High Price	Volume on date of High Price (No. of Equity Shares)	Low Price	Date of Low Price	Volume on date of Low Price (No. of Equity Shares)	Average Market Price of the Equity Shares for the year
25-26	2,139.30	30.06.2025	7,574	793.95	27.01.2026	11,792	1229.50
24-25	1,545	14.10.2024	13,769	685	05.06.2024	7,623	1132.62
23-24	978.9	05.02.2024	32,085	514	25.04.2023	15,025	713.82

NSE:

Fiscal Year	High Price	Date of High Price	Volume on date of High Price (No. of Equity Shares	Low Price	Date of Low Price	Volume on date of Low Price (No. of Equity Shares)	Average Market Price of the Equity Shares for the year
25-26	2,138	30.06.2025	2,18,801	792.50	27.01.2026	1,02,961	1229.87
24-25	1,548.95	14.10.2024	3,08,209	678.55	05.06.2024	1,42,062	1,133.20
23-24	976	05.02.2024	6,57,772	512.35	25.04.2023	1,31,980	713.95

U. ANY MATERIAL DEVELOPMENT AFTER THE DATE OF THE BALANCE SHEET:

1. Our Company received In-Principle approval from both BSE and NSE vide letter no. DCS/AMAL/IP/TS/278/2026-27 dated October 14, 2026 and letter no. NSE/LIST/204 dated October 15, 2026 respectively.
2. Further, our Company was also granted an exemption from the application of Rule 19(2) (b) of the Securities Contracts (Regulation) Rules, 1957 by the SEBI vide the letter no. I/23931/2026 dated October 16, 2026.
3. Except as disclosed above and in the Information Memorandum, to the knowledge of the Company, there are no circumstances which have arisen since the last Audited Financial Statements disclosed in the Information Memorandum which may materially or adversely affect or are likely to affect the Company's operations, profitability or value of the assets.

V. SUCH OTHER INFORMATION AS MAY BE SPECIFIED BY THE BOARD FROM TIME TO TIME

The Information Memorandum shall be made available on the Company's website at https://iglspirits.com/.

For and on behalf of Board of
IGL Spirits Limited

Sd/-
Ishan Khanna
Company Secretary and Compliance Officer
Membership No: A53517

Place : Noida, Uttar Pradesh
Date : October 22, 2026

SapphireFoods

सफायर फूड्स इंडिया लिमिटेड

पंजीकृत कार्यालय : एससीओ–328, सेक्टर–9, पंचकुला – 134109, हरियाणा
कॉर्पोरेट कार्यालय : 702, प्रिज्म टावर, ए विंग, माइंडस्पेस, लिंक रोड, गोरेगांव (पश्चिम), मुंबई – 400062
कॉर्पोरेट पहचान संख्या (सीआईएन) : L55204HR2009PLC145722, **दूरभाष सं.:** 022 67522300
ईमेल : investor@sapphirefoods.in, **वेबसाइट :** www.sapphirefoods.in

30 सितंबर 2026 को समाप्त तिमाही तथा छमाही के अलेखापरीक्षित वित्तीय परिणामों (पृथक एवं समेकित) का विवरण (सेबी (एलओडीआर) विनियमावी, 2015 के विनियम 47 के साथ पठित विनियम 33)

निदेशक मंडल ने 22 अक्टूबर 2026 को आयोजित अपनी बैठक में अन्य बातों के साथ–साथ, 30 सितंबर 2026 को समाप्त तिमाही तथा छमाही के कंपनी के अलेखापरीक्षित वित्तीय परिणामों (पृथक एवं समेकित) पर विचार किया तथा उन्हें स्वीकृत किया। सीमित समीक्षा रिपोर्टों के साथ वित्तीय परिणाम, कंपनी की वेबसाइट **https://www.sapphirefoods.in/investors-relation/financials** पर उपलब्ध हैं तथा क्यूआर कोड स्कैन करके भी प्राप्त किए जा सकते हैं।

निदेशक मंडल हेतु तथा उसकी ओर से
हस्ता./–
संजय पुरोहित
पूर्णकालिक निदेशक तथा समूह के सीईओ
डीआईएन : 00117676

स्थान : मुंबई
तिथि : 22 अक्टूबर 2026

Glenmark
A new way for a new world

ग्लेनमार्क फार्मास्यूटिकल्स लिमिटेड

सीआईएन: L24299MH1977PLC019982
रजिस्टर्ड ऑफिस: बी/2, महालक्ष्मी चैंबर्स, 22, भुलाभाई देसाई रोड, मुंबई – 400 026.
फ़ोन नंबर: +91 22 4018 9999 • **फ़ैक्स नंबर:** +91 22 4018 9986

सार्वजनिक सूचना

सभी संबंधितों को सूचित किया जाता है कि व्यापार मार्जिन युक्तिकरण (टीएमआर) के संबंध में राष्ट्रीय औषधि मूल्य निर्धारण प्राधिकरण (''एनपीपीए'') द्वारा जारी अधिसूचना एस.ओ. 5690 (ई), दिनांक 17 अक्टूबर, 2026 के अनुसरण में गैर–अनुसूचित कैंसर रोधी दवाओं की सस्ती कीमतों पर उपलब्धता सुनिश्चित करने के उद्देश्य से टीएमआर ढांचे के अंतर्गत आने वाले ग्लेनमार्क उत्पादों पर लागू जीएसटी सहित संशोधित अधिकतम खुदरा मूल्य (''एमआरपी'') 9 नवंबर 2026 से प्रभावी होगा और निम्नानुसार होगा:

लागू ग्लेनमार्क उत्पादों के संशोधित एमआरपी को क्यूआर कोड स्कैन करके एक्सेस किया जा सकता है.

ग्लेनमार्क के सभी चैनल भागीदारों, वितरकों, स्टॉकिस्टों, खुदरा विक्रेताओं, अस्पतालों, स्वास्थ्य केंद्रों आदि को एतद्द्वारा सलाह दी जाती है कि वे यह सुनिश्चित करें कि लागू कटौती के साथ 9 नवंबर, 2026 से प्रभावी होने वाली एमआरपी का पूरा लाभ सभी ग्राहकों को दिया जाए.